The dementia-associated APOE ε4 allele is not associated with REM sleep behavior disorder

Ziv Gan-Or, MD, PhD, Jacques Y. Montplaisir, MD, PhD, Jay P. Ross, BSc, Judes Poirier, PhD, Simon C. Warby, PhD, Isabelle Arnulf, MD, PhD, Stephanie Strong, BSc, Yves Dauvilliers, MD, PhD, Claire S. Leblond, PhD, Michele T.M. Hu, MBBS, FRCP, PhD, Birgit Högl, MD, Ambra Stefani, MD, Christelle Charley Monaca, MD, PhD, Valérie Cochen De Cock, MD, PhD, Michel Boivin, PhD, Luigi Ferini-Strambi, MD, PhD, Giuseppe Plazzi, MD, PhD, Elena Antelmi, MD, Peter Young, MD, Anna Heidbreder, MD, Thomas R. Barber, MA, MBBS, MRCP, Samuel G. Evetts, BSc Hons, MSc, Michal Rolinski, BM BCh, BA Hons, MRCP, Patrick A. Dion, PhD, Alex Desautels, MD, PhD, Jean-François Gagnon, PhD, Nicolas Dupré, MD, MSc, Ronald B. Postuma, MD, MSc, Guy A. Rouleau, MD, PhD

PII: S0197-4580(16)30242-1
DOI: 10.1016/j.neurobiolaging.2016.10.002
Reference: NBA 9741

To appear in: Neurobiology of Aging

Received Date: 18 August 2016
Revised Date: 22 August 2016
Accepted Date: 1 October 2016


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
The dementia-associated APOE ε4 allele is not associated with REM sleep behavior disorder

Ziv Gan-Or, MD, PhD, Jacques Y. Montplaisir, MD, PhD, Jay P. Ross, BSc, Judes Poirier, PhD, Simon C. Warby, PhD, Isabelle Arnulf, MD, PhD, Stephanie Strong, BSc, Yves Dauvilliers, MD, PhD, Claire S. Leblond, PhD, Michele T.M. Hu, MBBS, FRCP, PhD, Birgit Högl, MD, Ambra Stefani, MD, Christelle Charley Monaca, MD, PhD, Valérie Cohen De Cock, MD, PhD, Michel Boivin, PhD, Luigi Ferini-Strambi, MD, PhD, Giuseppe Plazzi, MD, Elena Antelmi, MD, Peter Young, MD, Anna Heidbreder, MD, Thomas R Barber MA, MBBS, MRCP, Samuel G. Evetts BSc Hons, MSc, Michal Rolinski, BM BCh, BA Hons, Patrick A. Dion, PhD, Alex Desautels, MD, PhD, Jean-François Gagnon, PhD, Nicolas Dupré, MD, MSc, Ronald B. Postuma, MD, MSc, and Guy A. Rouleau, MD, PhD.

Affiliations:

Montreal Neurological Institute, McGill University, Montréal, QC, H3A 0G4, Canada, Department of Human Genetics, McGill University, H3A 0G4, Montréal, QC, Canada, Department of Neurology and neurosurgery, McGill University, Montréal, QC, H3A 0G4, Canada, Centre d’Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, QC, H4J 1C5, Canada, Department of Psychiatry, Université de Montréal, Montréal, QC, H3T 1J4, Canada, Department of Psychiatry, McGill University, Montréal, QC, H3A 0G4, Canada, Douglas Mental Health University Institute, Montréal, QC, H4H 1R3, Canada, Sleep Disorders Unit, Pitié Salpêtrière Hospital, Centre de Recherche de l’Institut du Cerveau et de la Moelle Epinière and Sorbonne Universities, UPMC Paris 6 univ, Paris, 75013, France, Sleep Unit, National Reference Network for Narcolepsy, Department of Neurology Hôpital-Gui-de Chauliac, CHU Montpellier, INSERM U1061, Montpellier, 34000, France, Parkinson’s Disease Centre (OPDC), University of Oxford, Oxford, OX1 2JD, United Kingdom, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX1 2JD, United Kingdom, Sleep Disorders Clinic, Department of Neurology, Medical University of Innsbruck, Innsbruck, 6020, Austria, University Lille north of France, Department of clinical neurophysiology and sleep center, CHU Lille, Lille, 59000, France, Sleep and neurology unit, Beau Soleil Clinic, Montpellier, 34070, France, EuroMov, University of Montpellier, Montpellier, 34095, France, GRIP, École de psychologie, Université Laval, Quéc city, QC, G1V 0A6, Canada, Institute of Genetic, Neurobiological and Social Foundations of Child Development, Tomsk State University, Tomsk, 634050, Russia, Department of Neurological Sciences, Università Vita-Salute San Raffaele, Milan, 20132, Italy, Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, 40126, Italy, IRCCS, Institute of Neurological Sciences of Bologna, Bologna, 40139, Italy, Department of Sleep Medicine and Neuromuscular Disorders, University of Muenster, 48149, Germany, Department of Neurosciences, Université de Montréal, Montréal, H3T 1J4, Canada, Département de psychologie, Université du Québec à Montréal, Montréal, QC, H2L 2C4, Canada, Faculté de Médecine, Université Laval, CHU de Québec (Enfant-Jésus), Québec, QC, G1J 1Z4, Canada, Department of Neurology, Montreal General Hospital, Montréal, QC, H3G 1A4, Canada.
Correspondence:

Ziv Gan-Or  
Montreal Neurological Institute, McGill University  
1033 Pine Avenue, West,  
Ludmer Pavilion, room 327  
Montreal, QC, H3A 1A1  
Phone: +1-514-398-6821  
e-mail: ziv.gan-or@mail.mcgill.ca
Abstract: The current study aimed to examine whether the APOE ε4 allele, associated with dementia with Lewy bodies (DLB), and possibly with dementia in Parkinson’s disease (PD), is also associated with idiopathic REM sleep behavior disorder (RBD). Two SNPs, rs429358 and rs7412, were genotyped in RBD patients (n=480) and in controls (n=823). APOE ε4 allele frequency was 0.14 among RBD patients and 0.13 among controls (OR=1.11, 95% CI 0.88-1.40, p=0.41). APOE ε4 allele frequencies were similar in those who converted to DLB (0.14) and those who converted to PD (0.12) or multiple system atrophy (0.14, p=1.0). The APOE ε4 allele is neither a risk factor for RBD nor it is associated with conversion from RBD to DLB or other synucleinopathies.

1. Introduction: Rapid eye movement (REM) sleep behavior disorder (RBD) is currently the strongest clinical prodromal feature preceding the development of an overt synucleinopathy, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA) (Iranzo, et al., 2014). One of the strongest genetic factors associated with DLB is the APOE epsilon4 (ε4) allele (Pickering-Brown, et al., 1994), and PD patients who carry this allele may be at increased risk for developing dementia. Since both RBD and the APOE ε4 allele are possibly associated with DLB, and with dementia in PD patients, we aimed to examine whether the APOE ε4 allele is associated with RBD and conversion to DLB. See Supplementary file for detailed introduction and full list of references.

2. Methods: The study population included idiopathic RBD patients (n=480) and controls (n=823) of European ancestry. RBD patients were diagnosed using clinical interview and polysomnography according to the ICSD-2 (International Classification of Sleep Disorders, version 2) criteria. The control group was composed of 253 elderly controls (age 59.5±9.8 years, matched to the available age at onset (AAO) of RBD, n=307, age 59.2±11.5), 510 young controls (age 34.0±6.5 years), and additional 60 controls with no available data on age. All control groups had nearly identical frequencies of the APOE ε4 allele (0.13, 0.13 and 0.14, respectively), which allowed us to analyze all controls combined. All
individuals signed informed consent forms at enrollment, and the study protocols were approved by the respective institutional review boards. DNA was extracted using a standard salting-out protocol. Two single nucleotide polymorphisms (SNPs), rs429358 and rs7412, were genotyped using TaqMan SNP genotyping assays. Genotypes were called using the QuantStudio™ 7 Flex Real-Time PCR System and Software (v 1.0). Goodness of fit test with one degree of freedom was applied to look for deviation from the Hardy-Weinberg equilibrium (HWE) among the controls. Differences in APOE allele or carriage frequencies were analyzed using the Fisher’s exact test, and differences in continuous variables were analyzed using t-test. A logistic regression model with age and sex as covariates was also applied. All statistical analysis was done using SPSS statistics V.23 (IBM Inc.). Detailed methods can be found in the supplementary file.

3. Results: The allele frequency of APOE ε4 was 0.14 among RBD patients and 0.13 among controls (OR=1.11, 95% CI 0.88-1.40, p=0.41). Overall, 25.8% of RBD patients carried at least one APOE ε4 compared to 23.0% among controls (p=0.25, Fisher’s exact test), and there were more homozygous carriers of the APOE ε4 allele among controls (3.2%) as compared to RBD patients (2.7%). Logistic regression model adjusted for age and sex also demonstrated lack of association between APOE ε4 allele carriage and risk for RBD (OR = 1.25, 95% CI 0.87-1.79, p=0.23). There was no difference in AAO when comparing carriers (n=88) and non-carriers (n=219) of the APOE ε4 allele (59.1 ± 8.4 vs. 59.3 ± 12.6 years, respectively, p=0.92, t-test). A total of 140 RBD patients (29.2%) were reported to have converted to either PD (n=98, 70% of the converters), dementia/DLB (n=28, 20%) or MSA (n=14, 10%). The carrier frequencies of one or more APOE ε4 in these groups were similar; 23.5%, 25.0% and 28.6%, respectively (p=0.91), and the allele frequencies were 0.12, 0.14 and 0.14 (p=1.0). The APOE ε4 allele frequency among those that did not convert was slightly higher, 0.15 (Table 1), with a total of 26.5% carriers of at least one APOE ε4 allele, compared to 24.3% among those who converted (p=0.65). More detailed results can be found in the supplementary file.
4. Discussion: Although RBD is a strong risk factor for developing DLB, and although DLB was reported to be associated with the \( APOE \) \( \varepsilon4 \) allele, our results demonstrate lack of association between the \( APOE \) \( \varepsilon4 \) allele and RBD or its age at onset. These and previous results further suggest that RBD may have a distinct genetic background; it is associated with \( GBA \) mutations (Gan-Or, et al., 2015b), but unlike PD it is not associated with \( LRRK2 \) mutations (Fernandez-Santiago, et al., 2016), and unlike DLB it is not associated with the \( APOE \) \( \varepsilon4 \) allele. Thus far, \( GBA \), \( SCARB2 \), and potentially \( SNCA \) (Gan-Or, et al., 2015a) overlap between RBD, PD and DLB (Supplementary Figure 1, see Supplementary file). Whether RBD has additional, unique genetic factors that were not identified in PD or DLB cohorts is still to be determined. Our current study identified similar frequencies of \( APOE \) \( \varepsilon4 \) allele in those who progressed to PD, DLB and MSA, suggesting that \( APOE \) alleles do not affect the type of subsequent synucleinopathy. Our study has some limitations, and a more detailed discussion including full list of references can be found in the supplementary file. Our results support a distinct genetic background for RBD-associated neurodegeneration, probably suggesting a specific genetic association with synucleinopathy rather than tauopathy/amyloidopathy.

References:
Disclosure statement

ZGO received consultation fees from Sanofi/Genzyme. JYM reports grants from Merck, GlaxoSmithKline, received speaking honoraria from Valeant Pharmaceutical, and Otsuka Pharmaceutical, serves on the advisory boards of Sanofi-Aventis, Servier, Merck, Jazz Pharma, Valeant Pharma, Impax Laboratories, Glaxo-SmithKline, UCB Canada, received consultancy fees from Otsuka Pharma, and Valeant Pharma. JPR reports no conflict of interests. JP reports no conflict of interests. SCW received honoraria from Pfizer, Bristol-Myers Squibb, SmithKline Beecham and Eli Lilly. IA received speaker honoraria form UCB Pharma. SS reports no conflict of interests. YD is on the advisory board and received travel and consultancy fees from UCB Pharma, bioprojet, and Jazz Pharma. CSL reports no conflict of interests. MTH reports no conflict of interests. BH received grant from UCB, speaker honoraria from UCB, Otsuka, Abbvie, Lundbeck, Lilly, Mundipharma. Serving on advisory boards or consulting for Mundipharma, Axovant. Received travel support from Habel Medizintechnik, Vivisol. AS reports no conflict of interests. CCM received fees for serving on advisory board of UCB pharma, lecture fees from UCB Pharma, Orkyn. VCD received funding from Orkyn, LVL medical, Teva and UCB. MB reports no conflict of interests. LFS reports no conflict of interests. GP served on the advisory board of UCB pharma, Jazz pharmaceuticals and Bioprojet. EA reports no conflict of interests. PY received honoraria for speakers bureaus by Sanofi Genzyme, Biomarin, UCB pharma, Medice, ResMed and Heinen und Loewenstein. Member of advisory boards for Sanofi Genzyme, Biomarin, Vanda and Medice. AH received travel support Habel Medizintechnik, received lecture honoraria from UCB, Heinen und Löwenstein. TRB reports no conflict of interests. MR reports no conflict of interests. PAD reports no conflict of interests. AD received research grants from Novartis pharma, Jazz Pharmaceuticals, Biron soins du sommeil. Received speaker honoraria from UCB and Paladin labs.

Acknowledgements

We would like to thank all the participants in the study. This work was funded by a grant to ZGO from the Michael J. Fox Foundation for Parkinson’s research. Part of this work was funded by an interface grant to IA from INSERM. The French DNA collection was promoted by the Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil (ADOREPS), project PARAGEN, PI Isabelle Arnulf. The Oxford Discovery cohort was funded by the Monument Trust Discovery Award from Parkinson’s UK and supported by the National Institute for Health Research (NIHR), Oxford Biomedical Research Centre based at Oxford University Hospitals, NHS Trust, University of Oxford, and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). Part of this work was funded by the Weston Brain Institute (grants to JYM and JP) and the J.L. Levesque Foundation (grant to JP). Part of this work was funded by grants to PY from the Lowensteinstiftung and the German Ministry of Education and Science (BMBF). ZGO is supported by a postdoctoral fellowship from the CIHR. JFG holds a Canada Research Chair on Cognitive Decline in Pathological Aging. GAR holds a Canada Research Chair in Genetics of the Nervous System and the Wilder Penfield Chair in Neurosciences. We thank Cynthia Bourassa, Sandra Laurent, Helene Catoire, Pascale Hince and Vessela Zaharieva for their assistance.
Table 1. *APOE* haplotypes in individuals with RBD and controls

<table>
<thead>
<tr>
<th></th>
<th>ε2/ε2  n, (%)</th>
<th>ε2/ε3  n, (%)</th>
<th>ε3/ε3  n, (%)</th>
<th>ε2/ε4  n, (%)</th>
<th>ε3/ε4  n, (%)</th>
<th>ε4/ε4  n, (%)</th>
<th>Total carriers of ε4, n (%)</th>
<th>ε4 allele frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RBD patients, n=480</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 (0.8)</td>
<td>51 (10.6)</td>
<td>301 (62.7)</td>
<td>4 (0.8)</td>
<td>107 (22.3)</td>
<td>13 (2.7)</td>
<td>124 (25.8)</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>RBD converted to synucleinopathy(^a), n=140</strong></td>
<td>3 (2.1)</td>
<td>12 (8.6)</td>
<td>91 (65.0)</td>
<td>1 (0.7)</td>
<td>32 (22.9)</td>
<td>1 (0.7)</td>
<td>34 (24.3)</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>RBD not converted to synucleinopathy, n=340</strong></td>
<td>1 (0.3)</td>
<td>39 (11.5)</td>
<td>210 (61.8)</td>
<td>3 (0.9)</td>
<td>75 (22.1)</td>
<td>12 (3.5)</td>
<td>90 (26.5)</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>Controls, n=823</strong></td>
<td>5 (0.6)</td>
<td>111 (13.5)</td>
<td>518 (62.9)</td>
<td>14 (1.7)</td>
<td>149 (18.1)</td>
<td>26 (3.2)</td>
<td>189 (23.0)</td>
<td>0.13</td>
</tr>
</tbody>
</table>

n, number; RBD, REM sleep behavior disorder

\(^a^\) PD, dementia/DLB or MSA
The dementia-associated APOE e4 allele is not associated with REM sleep behavior disorder

Ziv Gan-Or, MD, PhD,a,b,c. Jacques Y. Montplaisir, MD, PhD,d,e. Jay P. Ross, BSc,b. Judges Poirier, PhDf,g, Simon C. Warby, PhD,h,i. Isabelle Arnulf, MD, PhD,j,k. Stephanie Strong, BSc,a. Yves Dauvilliers, MD, PhD, Claire S. Leblond, PhD, Michel T.M. Hu, MBBS, FRCP, PhD, Birgit Högl, MD, Ambra Stefani, MD, Christelle Charley Monaca, MD, PhD, Valérie Cohen De Cock, MD, PhD, Michel Boivin, PhD, Luigi Ferini-Strambi, MD, PhD,r. Giuseppe Plazzi, MD, PhD,s,t, Elena Antelmi, MD, Peter Young, MD, Anna Heidbreder, MD, Thomas R Barber MA, MBBS, MRCP, Samuel G. Evetts BSc Hons, MSc,j,k, Michal Rolinski, BM BCh, BA Hons, MRCP, Patrick A. Dion, PhD, Alex Desautels, MD, PhD, Jean-François Gagnon, PhD, Nicolas Dupré, MD, MSc, Ronald B. Postuma, MD, MSc,c,y, and Guy A. Rouleau, MD, PhD,a,b,c.

Affiliations:
a Montreal Neurological Institute, McGill University, Montréal, QC, H3A 0G4, Canada, b Department of Human Genetics, McGill University, H3A 0G4, Montréal, QC, Canada, c Department of Neurology and neurosurgery, McGill University, Montréal, QC, H3A 0G4, Canada, d Centre d’Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, QC, H4J 1C5, Canada, e Department of Psychiatry, Université de Montréal, Montréal, QC, H3T 1J4, Canada, f Department of Psychiatry, McGill University, Montréal, QC, H3A 0G4, Canada, g Douglas Mental Health University Institute, Montréal, QC, H4H 1R3, Canada, h Sleep Disorders Unit, Pitié Salpêtrière Hospital, Centre de Recherche de l’Institut du Cerveau et de la Moelle Epinière and Sorbonne Universities, UPMC Paris 6 univ, Paris, 75013, France, i Sleep Unit, National Reference Network for Narcolepsy, Department of Neurology Hôpital-Gui-de Chauliac, CHU Montpellier, INSERM U1061, Montpellier, 34000, France, j Oxford Parkinson’s Disease Centre (OPDC), University of Oxford, Oxford, OX1 2JD, United Kingdom, k Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX1 2JD, United Kingdom, l Sleep Disorders Clinic, Department of Neurology, Medical University of Innsbruck, Innsbruck, 6020, Austria, m University Lille north of France, Department of clinical neurophysiology and sleep center, CHU Lille, Lille, 59000, France, n Sleep and neurology unit, Beau Soleil Clinic, Montpellier, 34070, France, o EuroMov, University of Montpellier, Montpellier, 34095, France, p GRIP, École de psychologie, Université Laval, Québec city, QC, G1V 0A6, Canada, q Institute of Genetic, Neurobiological and Social Foundations of Child Development, Tomsk State University, Tomsk, 634050, Russia, r Department of Neurological Sciences, Università Vita-Salute San Raffaele, Milan, 20132, Italy, s Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, 40126, Italy, t IRCCS, Institute of Neurological Sciences of Bologna, Bologna, 40139, Italy, u Department of Sleep Medicine and Neuromuscular Disorders, University of Muenster, 48149, Germany, v Department of Neurosciences, Université de Montréal, Montréal, H3T 1J4, Canada, w Département de psychologie, Université du Québec à Montréal, Montréal, QC, H2L 2C4, Canada, x Faculté de
Médecine, Université Laval, CHU de Québec (Enfant-Jésus), Québec, QC, G1J 1Z4, Canada, 
Department of Neurology, Montreal General Hospital, Montréal, QC, H3G 1A4, Canada.

Correspondence:

Ziv Gan-Or
Montreal Neurological Institute, McGill University
1033 Pine Avenue, West,
Ludmer Pavilion, room 327
Montreal, QC, H3A 1A1
Phone: +1-514-398-6821
e-mail: ziv.gan-or@mail.mcgill.ca
Abstract

A significant proportion of individuals with REM sleep behavior disorder (RBD) will progress to dementia with Lewy bodies (DLB) and Parkinson’s disease (PD). We aimed to examine whether the \textit{APOE} ε4 allele, associated with DLB, and possibly with dementia in PD, is also associated with idiopathic RBD. The two SNPs tagging the different \textit{APOE} alleles (rs429358 and rs7412) were genotyped in individuals who were initially diagnosed with RBD (n=480) and in controls (n=823). \textit{APOE} ε4 allele frequency was 0.14 among RBD patients and 0.13 among controls (OR=1.11, 95% CI 0.88-1.40, \textit{p}=0.41), and this lack of association remained after adjustment for age and sex. Furthermore, allele frequencies of \textit{APOE} ε4 were similar in those who converted to DLB (0.14) and those who converted to PD (0.12) or multiple system atrophy (0.14, \textit{p}=1.0). The \textit{APOE} ε4 allele is neither a risk factor for RBD nor it is associated with conversion from RBD to DLB or other synucleinopathies.

\textbf{Key words:} REM sleep Behavior disorder, APOE
Introduction

Rapid eye movement (REM) sleep behavior disorder (RBD), characterized by lack of muscle atonia and enacting of dreams during REM sleep, is currently the strongest clinical prodromal feature preceding the development of an overt synucleinopathy. With long term follow-up, more than 80% of individuals with idiopathic RBD developed either Parkinson’s disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA) (Iranzo, et al., 2014, Schenck, et al., 2013). It was suggested that RBD may define a subtype of PD patients (Fereshtehnejad, et al., 2015, Gagnon, et al., 2004) with cognitive decline (Gagnon, et al., 2009, Vendette, et al., 2007), dementia (Anang, et al., 2014), hallucinations (Sixel-Doring, et al., 2011) and autonomic dysfunction (Postuma, et al., 2008), as compared to PD patients without RBD. In addition, pathological studies in brains of PD patients with and without RBD demonstrated a more widespread α-synuclein accumulation in those associated with RBD (Postuma, et al., 2015a).

If indeed RBD represents a subtype of PD, or a subtype of synucleinopathy, it is possible that it has specific genetic background. A preliminary study that examined the association of RBD with several genetic risk factors for PD identified an association mainly with MAPT and SCARB2, and marginal or lack of association with other markers (Gan-Or, et al., 2015a). A recent study suggested that RBD is associated with mutations in GBA in both idiopathic RBD and PD cohorts (Gan-Or, et al., 2015b). This association was stronger than the association of GBA mutations with PD in a similar population (Noreau, et al., 2011), suggesting that GBA may be one of the genetic factors that is more specific to RBD. Furthermore, the association of GBA mutations with DLB (Nalls, et al., 2013) also seems to be stronger than the association with PD (Sidransky, et al., 2009). Conversely, mutations in LRRK2 were not associated with RBD (Fernandez-Santiago, et al.,
2016, Pont-Sunyer, et al., 2015, Saunders-Pullman, et al., 2015), further supporting the hypothesis that RBD has a distinct genetic background.

One of the strongest genetic factors associated with DLB is the APOE epsilon4 (ε4) allele (Pickering-Brown, et al., 1994), and PD patients who carry this allele may be at increased risk for developing dementia (Pankratz, et al., 2006), although negative results were also reported for these associations (Jasinska-Myga, et al., 2007, Lovati, et al., 2010). Since both RBD and the APOE ε4 allele are possibly associated with DLB, and with dementia in PD patients, we aimed to examine whether the APOE ε4 allele is associated with RBD and conversion to DLB.

Methods

Population

The study population included consecutively recruited, unrelated idiopathic RBD patients (n=480) and controls (n=823) of European ancestry. RBD patients were collected by collaborators from the international RBD study group and were diagnosed using clinical interview and polysomnography according to the ICSD-2 (International Classification of Sleep Disorders, version 2) criteria (Thorpy, 2012). The control group was composed of 253 elderly controls (age 59.5±9.8 years, matched to the available age at onset (AAO) of RBD, n=307, age 59.2±11.5), 510 young controls (age 34.0±6.5 years), and additional 60 controls with no available data on age. However, all control groups had nearly identical frequencies of the APOE ε4 allele (0.13, 0.13 and 0.14, respectively), suggesting lack of age-effect, which allowed us to analyze all controls combined. All individuals signed informed consent forms at enrollment, and the study protocols were approved by the respective institutional review boards.
Genotyping

DNA was extracted using a standard salting-out protocol. To determine the APOE haplotypes, two tagging single nucleotide polymorphisms (SNPs), rs429358 and rs7412, were genotyped using TaqMan SNP genotyping assays (C___3084793_20 and C____904973_10, respectively, ThermoFisher Scientific Inc.) according to the manufacturer's instructions. Genotypes were called using the QuantStudio™ 7 Flex Real-Time PCR System and Software (v 1.0). Carriers of T in rs429358 and T in rs7412 were determined as carriers of the ε2 allele, carriers of T in rs429358 and C in rs7412 were determined as carriers of the ε3 allele, and carriers of C in rs429358 and C in rs7412 were determined as carriers of the ε4 allele. Of this cohort, the GBA gene was sequenced in 265 RBD patients (Gan-Or, et al., 2015b), and nine PD-associated SNPs were genotyped in 261 patients (Gan-Or, et al., 2015a).

Statistical analysis

Categorical variables are presented as percentage or frequencies, whereas continuous variables are presented as mean ± standard deviation. Goodness of fit test with one degree of freedom was applied to look for deviation from the Hardy-Weinberg equilibrium (HWE) among the controls. Differences in APOE allele or carriage frequencies were analyzed using the Fisher’s exact test, and differences in continuous variables were analyzed using t-test. To further avoid a potential bias due to age, and since sex distribution was different among patients with RBD vs. controls, a logistic regression model with age and sex as covariates was also applied. All statistical analysis was done using SPSS statistics V.23 (IBM Inc.).

Results
Lack of association between the APOE ε4, RBD risk and its age at onset

Table 1 details the different APOE alleles in RBD patients and controls. The frequency of the two SNPs defining the APOE alleles did not deviate from HWE. The allele frequency of APOE ε4 was 0.14 among RBD patients and 0.13 among controls (OR=1.11, 95% CI 0.88-1.40, p=0.41). Overall, 25.8% of RBD patients carried at least one APOE ε4 compared to 23.0% among controls (p=0.25, Fisher’s exact test), and there were more homozygous carriers of the APOE ε4 allele among controls (3.2%) as compared to RBD patients (2.7%). Logistic regression model adjusted for age and sex also demonstrated lack of association between APOE ε4 allele carriage and risk for RBD (OR = 1.25, 95% CI 0.87-1.79, p=0.23). Data on age at onset (AAO) of RBD was available for 307 individuals, and there was no difference in AAO when comparing carriers (n=88) and non-carriers (n=219) of the APOE ε4 allele (59.1 ± 8.4 vs. 59.3 ± 12.6 years, respectively, p=0.92, t-test).

The APOE ε4 allele is not associated with conversion to PD, DLB or MSA.

Since most of the patients in our cohort are being followed-up longitudinally, we examined whether the APOE ε4 allele is associated with conversion to either PD, dementia/DLB, or MSA. A total of 140 RBD patients (29.2%) were reported to have converted to either PD (n=98, 70% of the converters), dementia/DLB (n=28, 20%) or MSA (n=14, 10%). The carrier frequencies of one or more APOE ε4 in these groups were similar; 23.5%, 25.0% and 28.6%, respectively (p=0.91), and the allele frequencies were 0.12, 0.14 and 0.14 (p=1.0). The APOE ε4 allele frequency among those that did not convert was slightly higher, 0.15 (Table 1), with a total of 26.5% carriers of at least one APOE ε4 allele, compared to 24.3% among those who converted (p=0.65).
Discussion

Although RBD is a strong risk factor for developing DLB (Iranzo, et al., 2014, Postuma, et al., 2015b), and although DLB was reported to be associated with the APOE ε4 allele (Kobayashi, et al., 2011, Lane, et al., 2009, Pickering-Brown, et al., 1994), our results demonstrate lack of association between the APOE ε4 allele and RBD or its age at onset. These and previous results (Fernandez-Santiago, et al., 2016, Gan-Or, et al., 2015a, Gan-Or, et al., 2015b, Saunders-Pullman, et al., 2015) further suggest that RBD may have a distinct genetic background; it is associated with GBA mutations (Gan-Or, et al., 2015b), but unlike PD it is not associated with LRRK2 mutations (Fernandez-Santiago, et al., 2016, Saunders-Pullman, et al., 2015), and unlike DLB it is not associated with the APOE ε4 allele. Thus far, GBA, SCARB2, and potentially SNCA overlap between RBD, PD and DLB (Figure 1) (Bras, et al., 2014, Gan-Or, et al., 2015a, Gan-Or, et al., 2015b). Whether RBD has additional, unique genetic factors that were not identified in PD or DLB cohorts is still to be determined.

Since PD patients with RBD are likely to develop dementia and hallucinations (Anang, et al., 2014, Sinforiani, et al., 2008), eventually presenting a phenotype similar to DLB, and based on the current and previous genetic and post-mortem results (Postuma, et al., 2015a), we hypothesize that RBD-associated synucleinopathy (the central common area in Figure 1) is the same clinical-pathological entity, whether it is defined as parkinsonism first with subsequent dementia and hallucinations, or whether it is defined as DLB with subsequent parkinsonism. In that sense, RBD can be considered as a marker for diffuse synucleinopathy, which may be a better description of the disease than DLB or PD with dementia. Neuropathological data from GBA mutations carriers
also demonstrated a more diffuse synucleinopathy (Choi, et al., 2011, Neumann, et al., 2009, Wong, et al., 2004), further supporting this notion. However, others suggest that PD and DLB should remain separate entities, at least until better genetic, molecular and clinical data will allow better definitions of these diseases and their potential subgroups (Boeve, et al., 2016). It is possible that stochastic events, or other genetic or environmental factors, determine whether α-synuclein will first be deposited in brain areas associated with dementia and later in the areas associated with Parkinsonism, or vice versa (Lai, et al., 2008, Lai and Siegel, 2003). The observation that α-synuclein can spread in the brain in a prion-like fashion (Bernis, et al., 2015, Danzer, et al., 2009, Freundt, et al., 2012) may support a stochastic progression hypothesis, yet additional neuropathological studies are needed to examine this possibility. Therefore, there are two possible explanations for the lack of association between the APOE ε4 allele and conversion to DLB in our cohort. First, as previously suggested (Bras, et al., 2014), it is possible that the association of the APOE ε4 allele with DLB is due to the component of DLB patients who also have a tauopathy, and that the association of RBD with DLB is with those who have more pure synucleinopathy. Alternatively, since the majority of our cohort had not yet converted to an overt synucleinopathy, it is possible that once a larger number would convert, an association between APOE ε4 allele and conversion to DLB may arise. Hence, a follow-up study will be needed to determine this possibility.

The association of RBD with the more devastating synucleinopathy, MSA, also necessitates more study. Whether unique genetic or environmental factors affect the risk to progress from RBD to MSA is still unknown. Our current study identified similar frequencies of APOE ε4 allele in those who progressed to PD, DLB and MSA, suggesting that APOE is not one of these factors. Interestingly, a recent study suggested that GBA mutations are associated with
MSA as well, (Mitsui, et al., 2015) however this observation is awaiting replications in additional cohorts.

Our study has some limitations. The control population was younger than the RBD group. To tackle this limitation, we took two approaches. First, we demonstrated that the frequencies of the \( APOE \) \( \varepsilon4 \) allele were similar across generations (i.e. in the elderly and young control groups), which rules out a potential bias. Furthermore, we also performed a logistic regression model with adjustment for age, which further demonstrated lack of association between the \( APOE \) \( \varepsilon4 \) allele and RBD. Another possible limitation would stem from RBD patients being recruited in multiple centers, which could have led to a potential population dependent bias if some cohorts are enriched in \( APOE \) \( \varepsilon4 \) allele carriers. However, since the frequencies of the \( APOE \) \( \varepsilon4 \) allele were similar across centers, this possibility was ruled out.

To conclude, our results support a distinct genetic background for RBD-associated neurodegeneration, probably suggesting a specific genetic association with synucleinopathy rather than tauopathy/amyloidopathy. To examine the hypotheses raised by the current and previous work, larger studies are necessary, including genome wide association and next-generation sequencing studies focusing on RBD, and comparing them to results from PD, DLB and MSA.
Acknowledgements

We would like to thank all the participants in the study. This work was funded by a grant to ZGO from the Michael J. Fox Foundation for Parkinson’s research. Part of this work was funded by an interface grant to IA from INSERM. The French DNA collection was promoted by the Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil (ADOREPS), project PARAGEN, PI Isabelle Arnulf. The Oxford Discovery cohort was funded by the Monument Trust Discovery Award from Parkinson’s UK and supported by the National Institute for Health Research (NIHR), Oxford Biomedical Research Centre based at Oxford University Hospitals, NHS Trust, University of Oxford, and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). Part of this work was funded by the Weston Brain Institute (grants to JYM and JP) and the J.L. Levesque Foundation (grant to JP). Part of this work was funded by grants to PY from the Lowensteinstiftung and the German Ministry of Education and Science (BMBF). ZGO is supported by a postdoctoral fellowship from the CIHR. JFG holds a Canada Research Chair on Cognitive Decline in Pathological Aging. GAR holds a Canada Research Chair in Genetics of the Nervous System and the Wilder Penfield Chair in Neurosciences. We thank Cynthia Bourassa, Sandra Laurent, Helene Catoire, Pascale Hince and Vessela Zaharieva for their assistance.

Financial Disclosures

ZGO received consultation fees from Sanofi/Genzyme. JYM reports grants from Merck, GlaxoSmithKline, received speaking honoraria from Valeant Pharmaceutical, and Otsuka Pharmaceutical, serves on the advisory boards of Sanofi-Aventis, Servier, Merck, Jazz Pharma, Valeant Pharma, Impax Laboratories, Glaxo-SmithKline, UCB Canada, received consultancy fees from Otsuka Pharma, and Valeant Pharma. JPR reports no conflict of interests. JP reports no conflict of interests. SCW received honoraria from Pfizer, Bristol-Myers Squibb, SmithKline Beecham and Eli Lilly. IA received speaker honoraria form UCB Pharma. SS reports no conflict of interests. YD is on the advisory board and received travel and consultancy fees from UCB Pharma, bioprojet, and Jazz Pharma. CSL reports no conflict of interests. BH received grant from UCB, speaker honoraria from UCB, Otsuka, Abbvie, Lundbeck, Lilly, Mundipharma. Serving on advisory boards or consulting for Mundipharma, Axovant. Received travel support from Habel Medizintechnik, Vivisol. AS reports no conflict of interests. CCM received fees for serving on advisory board of UCB pharma, lecture fees from UCB Pharma, Orkyn. VCD received funding from Orkyn, LVL medical, Teva and UCB. MB reports no conflict of interests. LFS reports no conflict of interests. GP served on the advisory board of UCB pharma, Jazz pharmaceuticals and Bioproject. EA reports no conflict of interests. PY received honoraria for speakers bureaus by Sanofi Genzyme, Biomarin, UCB pharma, Medice, ResMed and Heinen und Löwenstein. Member of advisory boards for Sanofi Genzyme, Biomarin, Vanda and Medice. AH received travel support Habel Medizintechnik, received lecture honoraria from UCB, Heinen und Löwenstein. TRB reports no conflict of interests. SGE reports no conflict of interests. MR reports no conflict of interests. PAD reports no conflict of interests. AD received
research grants from Novartis pharma, Jazz Pharmaceuticals, Biron soins du sommeil. Received speaker honoraria from UCB and Paladin labs.
References


Figure 1. Venn diagram of the genetic overlap between PD, DLB and RBD.

While *GBA* mutations, *SCARB2* and possibly *SNCA* variants are associated with all three conditions, other genetic variants such as *APOE* ε4 in DLB and *LRRK2* mutations in PD are distinctively associated with each condition but not with RBD. It is therefore likely that RBD-associated neurodegeneration (the overlapping area of PD, DLB and RBD) may have distinct genetic background. While thus far no genetic variants that are uniquely associated with RBD were discovered, it is possible that such genetic risk factors do exist, and that they were not discovered in PD/DLB studies since RBD cases are diluted within the cohorts used to study these diseases.